König, AnnekatrinVicente Miranda, HugoOuteiro, Tiago Fleming2022-12-282022-12-282018-02-181877-7171PURE: 3657807PURE UUID: 7138ee80-d65f-49d7-8e33-9ba0faa071b3PubMed: 29480231WOS: 000425657100004Scopus: 85043588925http://hdl.handle.net/10362/146708Funding: Tecnologia (FCT), Portugal (SFRH/BPD/109347/ 2015; PTDC/NEU-OSD/5644/2014). TFO is supported by the DFG Center for Nanoscale Microscopy of the Brain (CNMPB) and by an EU Joint Programme – Neurodegenerative Disease Research (JPND) project (aSynProtec). The project is supported through the following funding organisations under the aegis of JPND – www.jpnd.edu (BMBF).Parkinson's disease (PD) is a neurodegenerative disorder with complex etiology and variable pathology. While a subset of cases is associated with single-gene mutations, the majority originates from a combination of factors we do not fully understand. Thus, understanding the underlying causes of PD is indispensable for the development of novel therapeutics. Glycation, the non-enzymatic reaction between reactive dicarbonyls and amino groups, gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). AGEs accumulate over a proteins life-time, and increased levels of glycation reaction products play a role in diabetic complications. It is now also becoming evident that PD patients also display perturbed sugar metabolism and protein glycation, including that of alpha-synuclein, a key player in PD. Here, we hypothesize that anti-diabetic drugs targeting the levels of glycation precursors, or promoting the clearance of glycated proteins may also prove beneficial for PD patients.11266099engGlycationMaillard-reactionParkinson’s diseasealpha-synucleinSDG 3 - Good Health and Well-beingreview10.3233/JPD-171285